ALFA FinderBSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,507.00
- Market cap
- ₹16,268 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 91.5×Sector 43.8×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India may receive a revised Bengaluru civic demand for improvement charges. Charges are likely capped at Rs.70.8 million plus interest, and Rs.156.1 million is already provided.
- Value
- ₹7.08 Cr
AstraZeneca Pharma India Results Update
AstraZeneca Pharma India reported 30% growth in Q2 results, with three new regulatory approvals. It also announced MoUs with two state governments.
AstraZeneca Pharma India Q2 FY27 Results: Net Profit ₹62.3 Cr, Up 14.9% YoY
AstraZeneca Pharma India Ltd reported revenue from operations of ₹729.1 Cr (+30.4% YoY) and net profit of ₹62.3 Cr (+14.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹62.3 Cr · +14.9% YoY
AstraZeneca Pharma India Legal & Regulatory
Delhi High Court directed NPPA to refrain from coercive steps on Rs.151.20 Crore alleged Symbicort Turbuhaler overcharging. Next hearing is January 11, 2027.
- Value
- ₹151.2 Cr
AstraZeneca Pharma India Other Announcement
AstraZeneca Pharma India filed its quarterly shareholding pattern for the period ended 30 September 2026. Promoter and promoter group hold 75% of total equity.
Other adverse business impact announcements
All →Konstelec Engineers Adverse Business Impact
Konstelec Engineers' registered office building was hit by a fire, and access has been restricted for about 10 days. Unaudited results for the quarter and half year ended September 30, 2026 are now expected by November 30, 2026.
Kanco Tea & Industries Adverse Business Impact
Kanco Tea & Industries disclosed a revised update on natural-calamity damage at its Bmaonpookrie Tea Estate. It has received Rs.224 lakhs from insurers, and the production loss is valued at Rs.303.41 lakhs.
- Value
- ₹3.03 Cr
Hindustan Organic Chemicals Adverse Business Impact
Hindustan Organic Chemicals will shut its Kochi phenol plant for about one week to replace a damaged hydrogen supply line. The shutdown is followed by hydrotesting and restoration work.
- Execution
- approximately one week
Gokaldas Exports Adverse Business Impact
Gokaldas Exports disclosed that a customer of its step-down subsidiary, The Children's Place, filed for Chapter 11 bankruptcy in the US. The subsidiary has a USD 4.11 Mn receivable from that customer, and the company is assessing the impact.
- Value
- ₹38.63 Cr
Medplus Health Services Adverse Business Impact
MedPlus stores in Karnataka face four-day drug licence suspensions. Expected financial impact is about Rs 4.06 lacs.
- Value
- ₹0.04 Cr
- Execution
- Four days
GRE Renew Enertech Adverse Business Impact
GRE Renew Enertech received Urjasol Energy's request to cancel a solar EPC purchase order. The company acknowledged the cancellation on 7 November 2026.
- From
- Urjasol Energy Private Limited